Pennsylvania Company Revolutionizes Memory Loss Intervention

HARRISBURG, Pa. - Dec. 10, 2021 - PRLog -- Pennsylvanians experiencing memory lapses now have access to a new and simple, technologically-advanced, cognitive assessment test that allows early intervention and treatment for those at risk of memory loss.

"Many adults experience forgetfulness or absentmindedness during everyday activities—misplacing car keys or the name of a television program—and fear they are experiencing memory loss due to the onset of dementia or Alzheimer's disease," says Michael Zarreii, Chief Science Officer of Axon Medical Technologies, LLC.

"In fact," Zarreii says, "most patients do not suffer from memory loss, but rather the challenges of memory access, which is normal—and treatable—rather than a serious health condition."

Intellig-EYES™ is a new, FDA- registered platform developed as part of a broader enhanced cognitive assessment system that provides data to physicians that can lead to early detection and treatment. Available in any physician's office and covered by insurance, the tool is a technological leap beyond existing industry gold standard cognitive assessments.

"Many people who suffer from memory loss don't seek treatment because they fear the label of a diagnosis, and frankly, don't know that treatments are available," Zarreii says. "When memory lapses occur is the ideal time to seek an assessment to identify the underlying cause and to allow early intervention and proper treatment."

Research shows that the vast majority of memory lapses are rooted in stress, anxiety, depression, or other treatable underlying issues. Only approximately five to six percent of memory lapse issues signify memory loss brought on by dementia or Alzheimer's disease. Knowing the underlying cause gives the patient peace of mind.

Studies also show that dementia-related memory loss due to neuron atrophy—the shrinking of the brain's information messengers—can begin as early as 17 years before diagnosis by subjective tests, since billions of neurons must be lost before the patient exhibits behaviors that testing detects. By then, Zarreii says, many neurons are lost and cannot be regained. When memory loss is detected early, doctors can monitor and manage a patient's condition and provide pharmacological or therapeutic treatments to stem the rate of memory loss, improve memory and cognitive function, and enhance quality of life.

For more information, see AxonMedicalTech.com (https://axonmedicaltech.com/sign-up/)'s website, contact (mailto:contact@axonmedicaltech.com) Axon Medical Technologies, or schedule an evaluation (https://axonmedicaltech.com/sign-up/) today.